Status:
UNKNOWN
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia
Lead Sponsor:
Istituto Clinico Humanitas
Collaborating Sponsors:
Celgene
Conditions:
Acute Myeloid Leukemia
IDH1 Gene Mutation
Eligibility:
All Genders
18-90 years
Brief Summary
Among the most notable cancer genome-wide sequencing discoveries in recent years was the finding of mutation hot-spots in the isocitrate dehydrogenase (IDH) genes in grade II/III astrocytomas and olig...
Detailed Description
Among the most notable cancer genome-wide sequencing discoveries in recent years was the finding of mutation hot-spots in the isocitrate dehydrogenase (IDH) genes in grade II/III astrocytomas and olig...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Diagnosis of AML According to 2016 WHO classification criteria
- Ability to give informed consent according to ICH/EU GCP, and national/local regulations.
Exclusion
- Lack of written informed consent
- Lack of biological samples (blood, bone marrow aspirate)
Key Trial Info
Start Date :
January 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 15 2020
Estimated Enrollment :
654 Patients enrolled
Trial Details
Trial ID
NCT04369287
Start Date
January 1 2016
End Date
December 15 2020
Last Update
May 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Clinico Humanitas
Milan, Italy